1 |
Lobas NH, Armitstead JA, Ivey MF. Expanding staff pharmacists' responsibilities to maintain pharmacy services in a neonatal intensive-care unit. Am J Hosp Pharm 1991;48(8):1708-11.
|
2 |
Mills B, Fensterheim L, Taitel M, Cannon A. Pharmacist-led Tdap vaccination of close contacts of neonates in a women's hospital. Vaccine 2014;32(4):521-5.
DOI
|
3 |
Simpson JH, Lynch R, Grant J, Alroomi L. Reducing medication errors in the neonatal intensive care unit. Arch Dis Child Fetal Neonatal Ed 2004;89(6):F480-2.
DOI
|
4 |
Schellack N, Gous AGS. An overview of the time needed to render critical ward services in a neonatal intensive care unit: documenting the activities of a clinical pharmacist: original research. S Afr Pharm J 2011;78(7):1-3.
|
5 |
Mulholland PJ. Pharmacists as non-medical prescribers: what role can they play? The experience in a neonatal intensive care unit. Eur J Hosp Pharm 2014;21:335-8.
DOI
|
6 |
de Jager Z, Schellack N, Gous A. What role does the clinical pharmacist play in the neonatal intensive care unit? S Afr Pharm J 2014;81(7):22-3.
|
7 |
Ragab MH, Al-Hindi MY, Alrayees MM. Neonatal parenteral nutrition: Review of the pharmacist role as a prescriber. Saudi Pharm J 2016;24(4):429-40.
DOI
|
8 |
Dunkley MK. Neonatal intensive care - an Australian survey of the pharmacist's role. Aust J Hosp Pharm 1991;21:104-8.
|
9 |
Krzyzaniak N, Bajorek B. A global perspective of the roles of the pharmacist in the NICU. Int J Pharm Pract 2017:25(2):107-20.
DOI
|
10 |
Kim SL, Lee JY, Ro SY, et al. Growth curves and factors associated with growth of premature infants during initial hospitalization. J Kor Soc Health-Syst Pharm 2002;19(3):243-8.
|
11 |
Yang HR, Choi CW, Kim BI, Seo JK, Choi SA, Kim SY. Clinical significance of the nutritional support team for preterm infants in a neonatal intensive care unit. Korean J Pediatr Gastroenterol Nutr 2009;12(1):39-45.
DOI
|
12 |
An SH, Kim JY, Gwak HS. Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. Am J Health Syst Pharm 2014;71(2):122-7.
DOI
|
13 |
Park TY, Kim YH, Jung YM, Lee JW, Lee ES. The comparison analysis of the prevention of adverse drug events through order interventions by designated-pharmacists. J Kor Soc Health-Syst Pharm 2014;31(1):638-43.
DOI
|
14 |
Jung JW, Kang YJ, Moon MY, et al. Preliminary study for economic evaluation of clinical pharmacist intervention. J Kor Soc Health-Syst Pharm 2011;28(4):327-36.
|
15 |
Kim YH, Rho JH, Suh YW, et al. Pharmacist interventions in neonatal intensive care unit associated cost avoidance and cost savings. J Kor Soc Health-syst Pharm 2018;35(3):281-91.
|
16 |
Oh YK, Lee GS, Rhie S. Neonatal total nutritional pharmacy service at intensive care unit at a university hospital in Korea. Korean J Clin Pharm 2013;23(2):167-74.
|
17 |
Taketomo CK, Hodding JH, Kraus DM. Pediatric & Neonatal Dosage Handbook, 19th ed. Hudson, OH: Lexi-Comp, 2012; 787-90, 1715-19.
|
18 |
Doh HJ, Yoon IK, Choi KS, et al. Evaluation of empiric vancomycin dosing regimens among neonates in a Korean tertiary care hospital. J Kor Soc Health-syst Pharm 2016;33(2):130-40.
|
19 |
Choi DW, Ye KN, Kim JT, An SH. Phenobarbital dosing and therapeutic drug monitoring in the neonatal intensive care unit. Yakhak Hoeji 2018;62(1):49-53.
DOI
|
20 |
Kim SL, Kim JY, An SH, Kang MK, Shin HY. Impact of clinical decision support system and clinical pharmacist in pediatrics. J Kor Soc Health-Syst Pharm 2006;23(2):95-103.
|
21 |
An SH, Kim JY, Song YC. Prevention of medication errors by clinical pharmacist and the computerized decision support system (CDSS) in neonatal intensive care unit. Pharmacotherapy 2009;29(3):128e
|
22 |
Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005;164(9):522-8.
|
23 |
Bae HJ, Shin YJ, Shin HJ, et al. Off-label drug use in neonatal intensive care unit: a tertiary center experience. J Kor Soc Healthsyst Pharm 2019;36(3):325-34.
|
24 |
Al-Turkait A, Szatkowski L, Choonara I, Ojha S. Review of drug utilization studies in neonatal units: a global perspective. Int J Environ Res Public Health 2020;17(16):E5669
|
25 |
Krzyzaniak N, Pawlowska I, Bajorek B. Review of drug utilization patterns in NICUs worldwide. J Clin Pharm Ther 2016;41(6):612-20.
DOI
|
26 |
Johnson MR, Nash DR, Laird MR, Kiley RC, Martinez MA. Development and implementation of a pharmacist-managed, neonatal and pediatric, opioid-weaning protocol. J Pediatr Pharmacol Ther 2014;19(3):165-73.
|
27 |
An SH. Contributing factors on pharmacokinetic variability in critically ill neonates. Korean J Clin Pharm 2017;27(2):63-8.
DOI
|
28 |
Willis ZI, Gillon J, Xu M, Slaughter JC, Di Pentima MC. Reducing antimicrobial use in an academic pediatric institution: Evaluation of the effectiveness of a prospective audit with real-time feedback. J Pediatric Infect Dis Soc 2017;6(4):339-345
|
29 |
Hamdy RF, Bhattarai S, Basu SK, et al. Vancomycin use in a level IV NICU. Pediatrics 2020;146(2):e20192963.
DOI
|
30 |
Krzyzaniak N, Pawlowska I, Bajorek B. The role of the clinical pharmacist in the NICU: a cross-sectional survey of Australian and Polish pharmacy practice. Eur J Hosp Pharm 2018;25(e1):e7-e16.
DOI
|
31 |
Leopoldino RD, Santos MT, Costa TX, Martins RR, Oliveira AG. Drug related problems in the neonatal intensive care unit: incidence, characterization and clinical relevance. BMC Pediatr 2019;19(1):134.
DOI
|
32 |
Nascimento ARFD, Leopoldino RWD, Santos METD, Costa TXD, Martins RR. Drug-related problems in cardiac neonates under intensive care. Rev Paul Pediatr 2020;38:e2018134.
DOI
|
33 |
Gray JE, Goldmann DA. Medication errors in the neonatal intensive care unit: special patients, unique issues. Arch Dis Child Fetal Neonatal Ed 2004;89(6):F472-3.
DOI
|
34 |
Loureiro CV, Fonteles MM, Mascarenhas MB, Chaves EF, Firmino PY. Medication follow-up in newborns with extremely low birthweight. Pharm Pract (Granada) 2019;17:1584.
DOI
|
35 |
Ohlinger J, Brown MS, Laudert S, Swanson S, Fofah O; CARE Group. Development of potentially better practices for the neonatal intensive care unit as a culture of collaboration: communication, accountability, respect, and empowerment. Pediatrics 2003;111:e471-81.
|
36 |
Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285(16):2114-20.
DOI
|
37 |
Dabliz R, Levine S. Medication safety in neonates. Am J Perinatol 2012;29(1):49-56.
DOI
|
38 |
Jain S, Basu S, Parmar VR. Medication errors in neonates admitted in intensive care unit and emergency department. Indian J Med Sci 2009;63(4):145-51.
DOI
|
39 |
Chappell K, Newman C. Potential tenfold drug overdoses on a neonatal unit. Arch Dis Child Fetal Neonatal Ed 2004;89(6):F483-4.
DOI
|
40 |
Chedoe I, Molendijk HA, Dittrich ST, et al. Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature. Drug Saf 2007;30(6):503-13.
DOI
|
41 |
Campino A, Lopez-Herrera MC, Lopez-de-Heredia I, Valls-i-Soler A. Educational strategy to reduce medication errors in a neonatal intensive care unit. Acta Paediatr 2009;98(5):782-5.
DOI
|
42 |
Cordero L, Kuehn L, Kumar RR, Mekhjian HS. Impact of computerized physician order entry on clinical practice in a newborn intensive care unit. J Perinatol 2004;24(2):88-93.
DOI
|
43 |
Johnson FL, Winship HW, Trinca CE. Neonatal medication surveillance by the pharmacist. Am J Hosp Pharm 1977;34(6):609-12.
|
44 |
Johnson CJ, Lobas NH, Ivey MF. Development of a pharmaceutical care system in a neonatal intensive care satellite pharmacy. Am J Hosp Pharm 1993;50(6):1158-63.
|
45 |
Dice JE, Burckart GJ, Woo JT, Helms RA. Standardized versus pharmacist-monitored individualized parenteral nutrition in lowbirth-weight infants. Am J Hosp Pharm 1981;38(10):1487-9.
|
46 |
Bryant BG. Clinical pharmacist emerging member of the NICU team. Neonatal Netw 1985;3(6):40-4.
|